NCT06183684招募中不适用
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 65
- 试验地点
- 12
- 主要终点
- Technical success
研究概览
简要总结
The objective of the study is to assess the safety and technical feasibility of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
详细描述
Early Feasibility (EFS), prospective, single-arm, multi-center study to evaluate safety and technical feasibility of the Laplace TTVR System in the treatment of severe, symptomatic tricuspid regurgitation patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 - 90 years of age at the time of the study procedure
- •Symptomatic tricuspid regurgitation despite being adequately treated with optimal medical therapy by the Local Heart Team for at least 30 days prior to the time of study consent.
- •Severe, massive or torrential tricuspid regurgitation determined by qualifying transthoracic echocardiogram (TTE) and/or transesophageal echocardiogram (TEE) using the 5-grade classification.
- •Candidate felt suitable for transcatheter tricuspid valve replacement as determined by the local heart team and confirmed by the patient selection committee. For patients with pre-existing trans-tricuspid pacemaker or ICD leads, the local heart team shall include an electrophysiologist.
- •Anatomically suitable for the Laplace TTVR system (with trans-jugular or transfemoral) access
- •Subject has provided informed consent and agrees to return for all required post-procedure follow-up visits
排除标准
- •Estimated life expectancy of less than 12 months
- •PVR >5 Wood units
- •Echocardiographic evidence of severe right ventricular dysfunction
- •Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation requiring treatment
- •Presence of significant congenital heart disease including but not limited to hemodynamically significant atrial septal defect, RV dysplasia, and arrhythmogenic RV.
- •Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery, within last 30 days. Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator or leadless pacemaker within 90 days prior to the study procedure
- •Stroke or other major cerebrovascular event within 90-days prior to index procedure
- •Untreated clinically significant coronary artery disease requiring revascularization, recent (within last 30 days) acute coronary syndrome or myocardial infarction.
- •Bleeding disorders including thrombocytopenia or platelet count <70,000 mm3 or thrombocytosis (platelet count >700,000 /mm3)
- •Current or planned pregnancy within next 12 months for women of childbearing potential
- •Active or recent endocarditis within last 90 days or, sepsis/ other systemic infection requiring oral or intravenous antibiotics within last 30 days
- •Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements. Any patient considered to be vulnerable.
- •Left ventricular ejection fraction (LVEF) < 30%
- •Contraindication or inability to complete transesophageal or intracardiac echocardiogram
研究组 & 干预措施
Tricuspid Valve Replacement
Experimental
Transcatheter replacement of the native tricuspid valve with the Laplace bioprosthesis
干预措施: Laplace TTVR System (Device)
结局指标
主要结局
Technical success
时间窗: During procedure
Successful valve implantation
次要结局
- Device success(30-days post-procedure)
- Procedural success(During procedure)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
不适用
Feasibility Study of the AblaCare System in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With Infertility Due to Polycystic Ovary SyndromePolycystic Ovary SyndromeInfertility, FemaleNCT05320289May Health5
进行中（未招募）
不适用
An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial FibrillationNon-valvular Atrial FibrillationNCT05565599Biosense Webster, Inc.58
终止
不适用
Safety and Feasibility Evaluation of the Arterica Closure Device designed for the closure of artery access sites following Endovascular proceduresACTRN12620000773932Arterica, Inc.4
招募中
不适用
MR-Guided Focused Ultrasound in the Treatment of Focal Epilepsy (EP001)EpilepsyNCT02804230InSightec20
撤回
不适用
Early Feasibility Study of the CardiAQ™ TMVI System (Transfemoral and Transapical DS)Mitral InsufficiencyHeart Valve DiseaseHeart DiseaseCardiovascular DiseaseNCT02515539Edwards Lifesciences